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Vaccination is the most effective medical intervention against diseases caused by human viral pathogens. Viral vaccines prevent or modify the
severity of illness in the individual and interrupt or reduce the transmission of the pathogens to other susceptible people. Through these
mechanisms, vaccines against smallpox, polio, measles and hepatitis B have had an enormous impact on world health over the last 50 years.
Advances in basic virology and understanding of human immunity promise more progress in the control of human viral diseases as the 21st
century begins. Some important targets, including human immunodeficiency virus, respiratory syncytial virus and hepatitis C virus present
challenges that require more basic research. The purpose of this review is to highlight four new viral vaccines that have recently, or will soon
demonstrate the effective translation of basic investigations into clinical benefits for disease control in healthy and high-risk populations. These
vaccines include the live attenuated vaccines against the RNA viruses, rotavirus and influenza A and B, and vaccines against human papilloma
virus and varicella-zoster virus, which are DNA viruses that cause morbidity and mortality through their capacity to establish persistent infection.
Although only the influenza vaccine has been licensed in the United States, these other new tools for disease prevention are likely to be introduced
within the next few years, with profound effects on the diseases that they cause. Hence, as Virology celebrates its 50th anniversary, it is appropriate
to examine these examples of recent advances in viral vaccines.
D 2005 Elsevier Inc. All rights reserved.
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Most viral vaccines are designed to prevent or moderate the
direct manifestations of infection with specific pathogens such
as the acute paralysis of polio or the acute respiratory illness of
influenza. However, viruses like human papillomavirus (HPV)
establish chronic infection and can cause more insidious and
delayed sequelae. While the genital infections associated with
certain strains of HPV are generally limited to the troubling
problem of genital warts, certain HPV types cause cervical,
vaginal and anal cancer many years after initial exposure and
represent a serious threat to human health. The most important
promise of HPV vaccines is reducing or even eradicating
cervical cancer.
Epidemiology and pathogenesis
Globally, cervical cancel kills approximately 273,000
women per year, second only to breast cancer (Ferlay et al.,
2004). Almost half a million new cases of invasive cervical
cancer occur each year, more than 80% of which are in poorer
countries, primarily in sub Saharan Africa, South America and
areas of South East Asia. Epidemiologic, animal model and
molecular studies carried out over the past 25 years have
proved that HPV infection is a necessary step in the
development of cervical cancer (Bosch et al., 2002; zur
Hausen, 2002; Walboomers et al., 1999).
Of the more than 100 HPV genotypes, approximately forty
have a predilection for infecting mucosal epithelium. A
relatively restricted number of these forty appear to play a
significant role in causing cervical cancer. Types 16 (54%), 18
(17%), 45 (7%), 31 (3%), 33 (3%), 52 (2%) and 58 (2%)
account for most cancer cases although the relative distribution
of types varies on a regional basis (Munoz et al., 2004). The
incidence of infection with genital HPV types increases very
soon after the initiation of sexual activity. The prevalence of
infection is highest in young women during their reproductive
years but then tends to fall, presumably because exposure rates
decline and most women spontaneously clear their infections
over time.
Much has been learned concerning the mechanisms by
which HPV causes cancer. Oncogenic HPV strains, which can
cause persistent infection, can integrate randomly into the host
genome which in turn disrupts the E2 ORF, leading to a loss of
transcriptional control of both E6 and E7 and persistent
expression of these proteins. Over-expression of these two
HPV non-structural genes appears to be associated with
enhanced E7 interactions with the Rb protein that promotecell proliferation and E6 enhancement of the degradation of
P53, which inhibits apoptosis (Chellappan et al., 1992; Thomas
et al., 1996; Scheffner et al., 1993; Slebos et al., 1994; Munger
et al., 2004).
Immunology
Information about the generation of immunity during natural
HPV infections is incomplete because of the lack of animal
models of HPV infection, the difficulty in growing this virus in
cell culture and the immune response in people appears to be
rather limited and slow to develop. However, most HPV
infections resolve naturally but immuno-suppression inhibits
this resolution (Sillman et al., 1997; Frazer, 1996). Presumably,
based on data from animal models, control of natural infection
is based on T cell effector functions, but this issue has not been
fully investigated in humans (Sillman et al., 1997; Frazer,
1996; Welters et al., 2003; Hopfl et al., 2000). The humoral
immune response to the two surface proteins (L1 and L2) of the
HPV icosahedral virion occurs slowly, at a low level (Carter et
al., 2000) and only in a subset of infected people. Definitive
data are not available to determine whether natural infection
with HPV induces immunity to re-infection with the same HPV
type but this does appear to be the case for some animal strains
(Jarrett et al., 1990).
Vaccines
Papilloma viruses are non-enveloped double stranded DNA
viruses with the capsid composed of two structural proteins, L1,
which is the major component, and L2. Early studies in animals
indicated that immunization with purified virions could induce
protection and these observations were followed by studies in a
number of laboratories indicating that recombinant viruses-like-
particles (VLPs) that had the structure and antigenic character-
istics of virions could be produced by expression of L1 or L1 and
L2 in high yield eukaryotic expression systems such as yeast or
baculovirus (Kirnbauer et al., 1992; Zhou et al., 1991; Kirnbauer
et al., 1993).
The ability to produce HPV VLPs in large amounts has
resulted in promising phase II clinical trials aimed at
preventing infection of sexually active young women with
highly oncogenic strains of HPV. In these studies, VLPs
derived from selected oncogenic strains of HPV were
administered by intramuscular injection. A yeast expressed
vaccine developed by Merck contains VLPs derived from
the two most common oncogenic HPV types, 16 and 18, as
well as VLPs derived from two common genital wart types,
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trials, primarily in young women in their late teens or early
twenties. It has generally been administered in a dose of 20
Ag–40 Ag in combination with an alum- based adjuvant.
These phase II studies showed a substantial reduction in the
incidence of infections with type 16 and 18 (as measured by
the detection of HPV in cervical isolates) or disease (as
measured by the presence of cervical intraepithelial neopla-
sia or CIN) in the range of 90–100% 17, (Koutsky et al.,
2002; Emeny et al., 2002), {Brown, 2004 #280}. Protection
has been observed for at least 36 months following
vaccination.
Similar Phase II results have been observed using a
candidate vaccine developed by GlaxoSmithKline (GSK)
and their partners containing HPV 16 and 18 VLP produced
in insect Spodoptera frugiperda SF9 cells and adjuvanted
with AS04, a mixture of aluminum hydroxide and 3
deacetylated monophosphoryl Lipid A (Harper et al.,
2004). Very high levels of protection against type 16 and
18 HPV infection as well as HPV-associated cervical
histologic abnormalities (93%) were observed in young
women up to 27 months following vaccination. Of interest,
very preliminary reports suggest that the GSK vaccine might
also induce some cross-protection against HPV types 31, 45
and 52 (Dubin et al., 2005). Both HPV VLP vaccines
appear to be generally safe and well tolerated with pain,
swelling and redness at the sight of injection being the
primary side effects. The Merck quadrivalent and the GSK
bivalent vaccines are now under study in large Phase III
trials which should definitively demonstrate the ability of
these vaccines to prevent acute and persistent HPV infection
with the oncogenic or genital HPV types included in the
vaccines, as well as to decrease or eliminate the appearance
of cervical intraepithelial neoplasia lesions, which are
associated with and the precursors of cervical cancer.
Expectations for the future
Expectations for the HPV vaccines are high, since they
appear, to be safe and well tolerated in large Phase II trials and to
protect against subsequent HPV infection and associated HPV
induced precancerous lesions very effectively. The possibility of
having a simple preventative measure that can significantly
reduce the global burden of cervical cancer a remarkable
achievement. However, many questions must be answered
before the full potential of these vaccines can be realized,
including:
(1) What is the optimal number of HPV types to include in a
vaccine and do the current vaccines induce any level of
type cross-reactive immunity to HPV types not present in
the vaccine?
(2) At what age should an HPV vaccine be given and to
whom (young women alone or both men and
women)?
(3) How long will the immunity induced with the current
vaccines last, will it differ between vaccines and willboosting doses be necessary to maintain immunity
through the period of HPV exposure?
(4) How will this modern ‘‘high tech’’ VLP based vaccine be
made available and affordable to people in the poorest
countries where it is needed most and will have the
greatest impact?
(5) How will wide-spread vaccination efforts affect current
cervical cancer screening recommendations and pro-
grams?
(6) How can we address the burden of disease in the very
large number of the world’s women already infected with
oncogenic HPV types for whom the current vaccines are
unlikely to be helpful?
Influenza virus
Influenza A and B viruses are the major pathogenic
influenza viruses in the human population (Wright, 2002).
Influenza A viruses are classified into subtypes based on two
surface antigens, hemagglutinin (HA) and neuraminidase
(NA). The frequent emergence of antigen variants through
antigenic drift forms the basis for seasonal influenza epidemics
that occur annually around the world. Antigenic shift, usually
caused by the reassortment of gene segments between two
influenza strains, occurs only in influenza A viruses in
permissive hosts and occurs infrequently compared to anti-
genic drift. The potential for a pandemic influenza arises when
antigen shift occurs because most adults as well as children
will not have any pre-existing immunity to the virus. The
intrinsic genetic variability of influenza viruses presents
obstacles for vaccination programs because the vaccines must
be reformulated frequently to incorporate viral antigens that
match the influenza A and B viruses predicted to circulate.
Progress in basic virology has provided new methods that
facilitate genetic manipulations of influenza (Palese and
Garcia-Sastre, 2002; Neumann et al., 1999; Hoffmann et al.,
2000). New information about the molecular mechanisms of
influenza replication and pathogenesis is emerging from
evaluating the consequences of deletions or mutations made
with these methods or with genetically engineered reassortants
(Palese and Garcia-Sastre, 2002). The standard influenza
vaccine is a trivalent inactivated (TIV) preparation, given by
intramuscular injection, which has generally been very
effective except in the elderly and during annual epidemics
when components of TIV do not match the circulating
influenza strain; experience with TIV efficacy in young
children is also more limited than in adults. A new live
attenuated influenza (LAIV) vaccine that is administered
intranasally was licensed in 2002 under the trade name Flumist
{MMWR, 2004 #342} with the intent of providing an
alternative approach to influenza vaccination. The probability
of an influenza pandemic constitutes a major public health
challenge that requires understanding the immunogenicity of
LAIV as well as TIV and designing new strategies for
providing large numbers of doses of vaccines that will rapidly
induce protective immunity in a completely naı¨ve population.
A.M. Arvin, H.B. Greenberg / Virology 344 (2006) 240–249 243Epidemiology and pathogenesis
Globally, influenza viruses cause large scale morbidity and
mortality every year, with an estimated 35,000 deaths in adults
>50 years old and an average of 114,000 excess hospitaliza-
tions each year in the United States {MMWR, 2004 #342}.
The seasonal winter outbreaks of influenza result from
antigenic drifts that occur every few years in each of the three
major Influenza viruses, H3N2, H1N1, and B, that are now
circulating and the introduction of new susceptibles into the
population. Influenza viruses are spread primarily by inhalation
of airborne viral particles aerosolized by coughing and
sneezing (Wright, 2002). The pathogenesis of influenza virus
infection begins with infection of the respiratory mucosal
epithelium. Influenza is an acute febrile illness associated with
myalgias, headache, cough, rhinitis, and otitis media, which is
usually self-limited but may progress to pneumonia. Encepha-
lopathy, myocarditis, and myositis are rare complications.
Under non-pandemic circumstances, the risk of influenza
morbidity and mortality is highest in persons >65 years old,
young children under 5 years, and persons with chronic cardiac
or pulmonary disease or immuno compromising conditions.
Because first encounters with influenza often cause lower
respiratory tract infection, the hospitalization rate for influenza
is 100 per 100,000 children, ages 0–4 years {MMWR, 2004
#342}. High infection rates in children of school age also
facilitate influenza spread. Influenza pandemics result from
antigenic shifts associated with reassortment events or emer-
gence of new strains from avian reservoirs, as occurred in
1918, 1957 and 1968 (Horimoto and Kawaoka, 2005). Under
these conditions, an influenza virus with an HA and/ or NA
that had not previously infected humans and that can infect,
cause disease and be transmitted efficiently, is introduced into a
large naı¨ve population. The potential risks of a new pandemic
are difficult to estimate accurately but such a pandemic will
constitute a major public health emergency.
Immunology
Influenza immunity is usually measured as serum IgG
antibodies to the HA and NA antigens of the circulating
influenza A and B viruses and high titers typically correlate
with a lower attack rate for infection and less severe influenza
disease (Wright, 2002). While convenient, this approach does
not evaluate other immune mechanisms, such as mucosal
antibodies and cell-mediated immunity. The higher suscepti-
bility of the host to serious influenza at the extremes of age is
likely to reflect diminished capacities of the innate and adaptive
immune system in the very young and the elderly. Young
children are often immunologically naı¨ve hosts and may also
have intrinsic limitations in immune cell function; immunose-
nescence in the elderly is characterized by poor responses to
infection or vaccination, despite repeated priming of memory
immunity. While HA antibodies in serum provide a correlate of
protection, influenza protection is likely to depend on a
repertoire of effector mechanisms provided by innate responses
as well as effector and memory B and T cells. Such responsesat both mucosal and systemic sites are presumed to be
necessary for natural and vaccine-induced protection but the
immune mechanisms and relative importance of each compo-
nent in the exposed or infected host is not known. Memory
CD4 and CD8 T cells that recognize influenza virus particles
and antigens are detectable by cytokine flow cytometry
methods (He et al., 2003). In addition to HA, cytotoxic T
cells can recognize the nucleoprotein (NP), matrix protein
(M1), nonstructural protein 1 (NS1), and polymerases (PB1
and PB2). Although these T cell responses are detected, their
role in the control of acute influenza infection or in protecting
the human host against re-infection is not well defined. Little is
known about influenza-specific B cells at the single cell level
or the homing of effector T or B cells to the respiratory tract
and the contribution of NK cells is poorly understood. Recent
experiments demonstrated IFN-gproduction by peripheral
blood NK cell subsets, as well as by influenza A-specific
memory CD8 T cells after exposure to influenza A virus; IL-2
production by T cells was required for the IFN-g response of
NK cells, indicating that memory T cells enhance innate NK-
mediated antiviral immunity (He et al., 2004).
Vaccines
The major immunogenic components of standard TIV
vaccines consist of HA and NA proteins from circulating flu
strains that are partially purified from detergent extracted,
inactivated virions and administered by intramuscular injection
(Fukuda, 2004). Inactivated influenza vaccines have been used
for 50 years and provide substantial, although not complete
protection in pediatric and adult populations; levels of
protection appear to be lower in the elderly. Information
documenting annual TIV efficacy is limited, especially as to
performance when the vaccine strain and the circulating strain
are not well matched. The newly licensed LAIV is made using
cold-adapted A/Ann Arbor/6/60 and B/Ann Arbor/1/66 strains
as the genetic Fbackbone_ into which HA and NA genes from
circulating strains are inserted by gene reassortment; the
genetic stability of the attenuation phenotype of the vaccine
viruses results from changes in several of the Fbackbone_ genes
that reduce virulence (Jin et al., 2003; Hoffmann et al., 2005).
LAIV is given as a large particle intranasal spray. Although
LAIV was licensed recently, vaccines derived from this
Fbackbone_ have been evaluated for more than 25 years
(Belshe, 2004a, 2004b). Several clinical studies carried out
over the past 10 years have documented LAIV safety and
capacity to induce protective immunity in children and healthy
adults. In a pivotal trial of LAIV in young children, substantial
levels of protection were observed after a single dose of
vaccine in a small subset of children who had failed to receive
their second dose (Belshe et al., 1998). In addition, several
studies have provided data to suggest that LAIV induces
considerable heterosubtypic immunity in recipients. Studies are
in progress to compare the efficacy and safety of LAIV and
TIV in young children less than 5 years of age and the relative
capacity of the two vaccine preparations to protect when one or
more of the vaccine components is mismatched with circulat-
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protection after TIV immunization but this correlation is not as
definitive after LAIV immunization, suggesting differences in
the mechanisms of protective immunity. Both vaccines induce
neutralizing antibodies, but the extent to which TIV and LAIV
induce T cell and mucosal immunity and whether the profiles
of cell-mediated and mucosal responses depend upon the
vaccine characteristics, the age of the vaccine recipient, or both
is not known. Protection following TIV correlates with
circulating antibody levels to HA 3–4 weeks after immuniza-
tion while immunity following natural infection or LAIV
seems to correlate better with mucosal IgA and anti-HA
antibodies. However, cellular immune correlates have not been
thoroughly examined. Some subjects given LAIV appear to
have protection without detectable serum or even nasal
antibody responses (Belshe et al., 2000a, 200b). Whether
protection is mediated by T cells or by B cell responses that are
not measured by current serologic assays is not known.
Recipients of LAIV also have evidence of protection even
when the circulating virus differs from vaccine strain (Belshe et
al., 2000a, 200b; Nichol et al., 1999; Halloran et al., 2003).
It is important to understand the differences in protective
mechanisms and kinetics of the induction of immune responses
after TIV and LAIV in order to develop optimal strategies to
use the two vaccines to reduce morbidity and mortality during
the annual epidemics and to prepare for the threat of a
pandemic. Use of adjuvant or alternative routes of TIV
administration, e.g., epidermal or intranasal inoculation, may
improve immunogenicity (Podda, 2001). Novel HA or NA
antigens expressed in LAIV could prove to be more immuno-
genic in the naive host than when given as inactivated antigens.
Production of both TIV and LAIV should be facilitated by
using reverse genetics and cell-based culture systems, which
would avoid the reliance on access to eggs and permit the
efficient generation of high yield reassortants. (Bruhl et al.,
2000; Halperin et al., 2002; Kemble and Greenberg, 2003).
Expectations for the future
NEW opportunities exist to achieve major advances in
preventing influenza epidemics and pandemics. Questions that
need to be addressed to help achieve these advances include:
(1) What are the mechanisms by which naı¨ve B and T cells
are primed to recognize influenza and the characteristics
of B and T cell memory immune responses after TIV
versus LAIV immunization, do they differ and if so,
how?
(2) What are the correlates of protection after LAIV and TIV
immunization and are they different?
(3) What mechanisms, in addition to antigenic drift and
shift, are used by influenza viruses to evade adaptive
immunity?
(4) Can the diminished responses to influenza vaccination in
the elderly and the need for multiple immunizations in
young naive children be overcome by modifications or
changes in current vaccination strategies or formulations?(5) Are there methods to elicit protective immunity against
conserved influenza proteins that will provide better
protection from year to year despite antigenic shifts?
(6) What is the optimal vaccine approach, using either TIVor
LAIV, or both, to control pandemic influenza?
(7) What strategies are required to make influenza vaccines
widely available to people in underdeveloped countries
during annual outbreaks and during a pandemic?
Rotavirus
Acute dehydrating diarrheal disease remains one of the most
common causes of morbidity and mortality worldwide with
most fatal cases occurring in less developed countries (Kosek
et al., 2003). Rotavirus infections are the single most important
etiologic agent of severe diarrhea in children under the age of 5
and have been estimated to result in approximately 440,000
deaths and 2.3 million hospitalizations each year in the world,
while in the United States, the annual estimates are 20–40
deaths and hospitalization rates of 55–80,000 (Parashar et al.,
2003; Hsu et al., 2005). The effort to reduce the global burden
of rotavirus disease suffered a serious reversal when a highly
effective, FDA-licensed vaccine (Rotashield, Wyeth, Inc.) was
withdrawn because of a temporal association between vaccine
administration and increased risk of intussusception of the
bowel in infants. Currently, two new, second generation live
attenuated rotavirus vaccines are poised for licensure in the
U.S. and/or Europe and elsewhere and it is hoped that these
new vaccines will be free of the rare but serious adverse effect
of intussusception.
Epidemiology and pathogenesis
Acute diarrheal disease of young children is caused by many
viral, bacterial, and parasitic pathogens, with the relative
contribution of these three classes of microbes differing by
geographic location, season and disease severity (O’Ryan et al.,
2005). However, in all environments, rotaviruses cause the
majority of cases of severe diarrhea in young children.
Rotaviruses are important enteric pathogens of many animal
species as well, but interspecies infections tend to be rare. The
genetic basis for this host range restriction is not well
understood but it forms the basis for several rotavirus vaccine
candidates. In humans, rotavirus infections tend to occur
seasonally in the cooler winter months in countries with
temperate climates but they occur throughout the year in the
tropics (Koopmans and Brown, 1999). Rotaviruses are triple
layered icosahedral viruses with a segmented doubled stranded
RNA genome and the two outer layer proteins, VP4 and VP7,
are both targets of neutralizing antibody and both specify viral
serotype, which is indicated by P type for VP4 and G type for
VP7. Human rotaviruses of several serotypes have been
isolated but most isolates are restricted to one of four G types
and one dominant P type (Santos and Hoshino, 2005).
Rotaviruses cause diarrhea by multiple mechanisms, including
direct cytolytic infection of mature villus tip enterocytes,
secretion of a virally encoded nonstructural protein that
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the enteric nervous or vascular systems which promote
secretion (Estes et al., 2001). The direct cytotoxic effects of
rotavirus on the gut appear to vary between species and the
recent evidence that rotavirus infection includes a well-defined
viremic phase (Blutt et al., 2003) all increase the complexity of
the pathogenesis of rotavirus disease.
Immunity
The specific determinants of immunity to rotavirus in humans
have not been fully identified. In mice, both T and B cells can
mediate the resolution of primary infection but T cells seem to
function more rapidly while protection from re-infection is
primarily a function of B cells and antibody, at least after natural
infection (Franco and Greenberg, 2001). Antibodies to both VP4
(P type) and VP7 (G type) can mediate protection and some
animal studies indicate that antibodies to NPS4 (the viral
enterotoxin) and VP6 (an internal structural protein) also have
protective activity. The role of type specific versus heterotypic
immunity in rotavirus infection is controversial, but it is clear
that infection in humans with a single rotavirus serotype
generally offers some protection against subsequent infection,
whether it is homotypic or heterotypic (Velazquez et al., 1996).
Several studies have attempted to correlate the level specific
serum or fecal antibody with protection but the results have been
variable. It is generally believed that if neutralizing antibodies of
any isotype are present in the gastrointestinal tract, they will
provide protection.
Vaccines
Live attenuated vaccines administered orally have been the
focus of most rotavirus immunization strategies, based on the
hypothesis that mucosal immunity in the gastrointestinal tract
was that the critical determinant of protection following natural
infection (Offit, 2002). Because a reverse genetic system is not
currently available to reduce virulence by directly modifying
the rotavirus genome, two traditional approaches have been
used to develop attenuated live viral vaccine candidates for
administration to young children. First, virulent human
rotavirus strains have been multiply passaged in cell culture
and the resultant strains tested for safety and immunogenicity.
A multiply passaged G1P8 strain was used to make the vaccine
candidate, Rotarix (GlaxoSmithKline). The molecular basis for
the attenuation of this strain has not been described but very
large scale safety studies indicate that the vaccine does not
cause diarrhea or other acute enteric disease compared to
placebo, whereas the parental isolate was virulent (Dennehy et
al., 2005; Vesikari et al., 2004; De Vos et al., 2004). Of note,
this rotavirus vaccine represents a single G and P serotype but
appears to afford protection against at least one (G9), and
probably several, other G type strains. The vaccine has been
shown to be highly efficacious in large Phase III clinical trials
in Latin America with efficacy rates against severe diarrhea of
at least 86%. This vaccine was not associated with intussus-
ception when evaluated in more than 60,000 infants in a verylarge randomized placebo control safety trial. Nevertheless,
even this large trial may not have been powered sufficiently to
detect rare intussusception events. Rotarixi was recently
licensed in Mexico and several other Latin American countries
and will be evaluated for approval in several European
countries in the near future.
A second approach to designing a live attenuated rotavirus
vaccine has been the ‘‘modified Jennerian’’ approach in which
an animal rotavirus strain (either bovine or simian) is employed
as a gene donor and, using classical genetic techniques, human
VP7 or VP4 encoding genes are reassorted into the genome of
the animal rotavirus. Such vaccines are predicted to be
attenuated based on host range restriction of the parental
animal strain in humans although the precise genetic basis for
such a restriction is not known. This strategy was used to create
Rotashield, which consisted of 4 separate viral strains expres-
sing the 4 most common human VP7 G types (1–4) on a
simian rotavirus genetic backbone. Rotashield was reactogenic
causing low grade fever in a significant number of infants, but
was highly effective at preventing severe diarrhea. It was
licensed and recommended for routine use in the United States
in 1998 but 9 months later was found to be associated with
intussusception and was withdrawn by the manufacturer
(Perez-Schael et al., 1997; Murphy et al., 2001). A second
generation reassortant vaccine derived from a bovine parental
strain, (RotaTeq, Merck and Co., Inc.) is now in the final stages
of evaluation. This pentavalent vaccine includes four common
human rotavirus G types (G1–4) as well as one very common
P type (P8). This vaccine, like the GSK attenuated human
strain candidate, is well tolerated by young children with little
if any reactogenicity and no association with intussusception in
a massive placebo-controlled safety study in more than 70,000
young children. The vaccine, in preliminary studies done
primarily in developed countries, was highly effective, eliciting
protection of about 75% against any rotavirus-associated
diarrhea and more than 90% against severe diarrhea (Clark et
al., 2004). Both the GSK and the Merck vaccine are produced
in Vero cells and both are administered orally to children at 2
and 4 months (Rotarix) or at 2, 4 and 6 months (RotaTeq) in
buffered diluents. Both are immunogenic but the relative
immunogenicity of the two candidates has not yet been directly
compared. Rotarixt, as might be expected of a fully human
strain, appears to be shed in greater amounts, for longer
periods, and, possibly, with more frequent transmission than
RotaTeq (Phua et al., 2005). RotaTeq is currently under
evaluation for licensure at the FDA.
The analysis of the risks and benefits of rotavirus vaccines
requires special discussion of the serious side effect of
intussusception. This is a complex topic and will only be
briefly reviewed. Intussusception is a common event in healthy
children during the first 12 months of life; it occurs when part
of the bowel telescopes into a more distal segment of gut and
thereby compromises the blood supply to the intestinal wall. If
not treated, intussusception can lead to bowel necrosis,
peritonitis and death. Post-licensure reporting by physicians
to the CDC/FDA Vaccine Adverse Events Surveillance
program detected a possible increase in the rate of intussus-
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hort and case control studies confirmed this association,
demonstrating a highly significant short-term increase of
>25-fold relative risk, primarily during the initial 1–2 weeks
following the first vaccine dose. What remains unclear is what
the actual increase in absolute risk of intussusception was, that
is, how many more total cases would be seen in vaccinated
children versus non vaccinated children. This absolute risk was
originally estimated to be approximately 1 additional case in
2500 vaccines but the estimate was later reassessed as being in
the range of 1 in 9474 vaccinated children (Murphy et al.,
2003). In fact, subsequent large scale epidemiologic studies of
children in the United States during the period in which
vaccine was widely distributed failed to detect any rise in the
actual number of cases of intussusception associated with the
vaccine (Simonsen et al., 2001). As a possible explanation for
this apparent paradox, Murphy et al. (2003) noted that the
increased relative risk of intussusception during the first 2
weeks after vaccination was followed by a significant
decreased risk, compared to controls. The subsequent decline
in relative risk of intussusception following vaccination
appeared to balance the short-term elevated risk and resulted
in little or no increase in overall or absolute risk. A new
analysis of the CDC case control data set has demonstrated that
much of the actual increased short term risk for intussusception
following Rotashield vaccination occurred in children who
received their first dose of vaccine after 3 months of age,
although the first dose was recommended to be given at 2
months (Simonsen et al., 2005). The estimated absolute risk for
intussusception in children who received Rotasheild doses at 2,
4 and 6 months of age, as recommended, was quite low and
was estimated to be approximately 1 in 11,000 to 16,000. Since
both the Rotarix and RotaTeq safety trials involved adminis-
tration of the first dose of vaccine, per protocol, at 2 months, it
seems quite possible that neither study was powered adequately
to detect the very low rate that would be predicted from the
Rotashield studies. These observations simply reinforce the
necessity for close post-licensure evaluations the Merck and
GSK vaccines when many hundreds of thousands or millions
of infants will be immunized.
Expectations for the future
Two second generation live attenuated rotavirus vaccines
are nearing licensure in the United States and/or Europe and
one is already licensed in several Latin American countries.
Both of these vaccines appear to be highly effective and safe in
very large trials designed to detect an associated risk of
intussusception. However, recent findings indicate that even
these very large pre-licensure studies may have been insuffi-
ciently powered to detect the expected increases in intussus-
ception rates in children initially vaccinated at 2 months of age.
Therefore, intensive post-licensure study will be required to
determine if these newer vaccines are actually free of the
previously encountered risks. On the other hand, the very clear
and substantial benefits that will be associated with the
implementation of an effective rotavirus vaccine program,especially in less developed countries, indicate that from a risk:
benefit perspective, the second generation vaccines are certain
to be highly advantageous for child health worldwide. Despite
the near term prospects for the availability of effective rotavirus
vaccines, a number of important questions remain to be
answered, including:
(1) How critical is the need for broad serotypic diversity in
the vaccine for prevention of rotavirus illness? Do the
two new vaccines differ in any significant way in their
ability to induce broad based immunity?
(2) Can these new vaccines be introduced into less deve-
loped countries, where the need is the greatest, in a cost
effective and timely manner?
(3) If the new vaccines have a rare association with
intussusception (less than 1:30,000) that becomes appa-
rent after licensure and wide-spread use, will these
vaccines also be withdrawn from use despite their
obvious utility from a risk, benefit perspective?
(4) What are the determinants of attenuation of the two new
vaccines and are they genetically stable?
(5) What are the best correlates of protection for rotavirus
vaccines?
(6) Do the vaccine viruses spread in the environment, and if
so, to what consequence?
Varicella-zoster virus
Varicella-zoster virus (VZV) is a medically important human
alpha herpes virus that causes varicella and herpes zoster in
healthy and immunocompromised patients (Arvin, 2001a,
2001b; Gilden et al., 2000). Live attenuated varicella vaccines,
derived from the VZV Oka strain, have been licensed for more
than a decade (Gershon, 2001). Routine universal immuniza-
tion, instituted in 1995, has had a major impact on varicella
incidence, hospitalizations and deaths in the United States
(Nguyen et al., 2005) but as expected, has not affected zoster
rates. Zoster-related morbidity is serious among older adults
and may be life-threatening in immunocompromised patients.
New investigations indicate that VZV vaccines may reduce the
risks of recurrent VZV infection in high-risk patients and in
healthy older adults (Hata et al., 2002; Oxman et al., 2005).
Epidemiology and pathogenesis
VZV is transmitted from varicella and herpes zoster skin
lesions that contain high concentrations of infectious virus.
Before immunization was introduced, the incidence of
varicella was ¨4 million cases per year in the United
States. Primary VZV infection, or varicella or ‘‘chickenpox’’,
is characterized by a cell-associated viremia, reflecting the T
cell tropism of VZV, and vesicular skin lesions. VZV gains
access to sensory ganglia of the cranial nerves, the dorsal
root ganglia and autonomic ganglia during primary infection,
presumably by retrograde transfer along neuronal axons,
viremia or both, and establishes latency in neurons. During
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sport to the skin, producing herpes zoster or ‘‘shingles’’,
characterized by a vesicular rash in the innervated derma-
tome. The estimated incidence of herpes zoster is >1 million
cases per year in the United States and complications,
especially post-herpetic neuralgia, are common (Gilden et
al., 2000). VZV reactivation destroys neurons and satellite
cells in the affected ganglia and causes extensive peripheral
neuropathy, which may lead to intractable pain and damage
to motor function. Recurrent VZV may lead to viremia and
disseminated infection in immunocompromised patients.
Immunology
Although both VZVantibodies and VZV-specific T cells are
induced, cell-mediated immunity is necessary to resolve primary
VZVinfection (Arvin, 2001a, 2001b). Adaptive CD4 and CD8T
cells that recognize VZV proteins persist in the healthy host,
along with VZV IgG antibodies that have neutralizing function.
Memory immunity to VZV may be determined by the initial
expansion of VZV T cells or by secondary stimulation
related to varicella exposures or sub-clinical reactivations, or
by all three mechanisms. Symptomatic second episodes of
varicella are rare but the risk of herpes zoster in older adults
and immunocompromised patients correlates with reduced T
cell proliferation and interferon-g production by peripheral
blood mononuclear cells stimulated with VZV and fewer
VZV-specific CD4 T cells. When VZV reactivates to cause
herpes zoster, VZV-specific T cells undergo a substantial and
sustained expansion (Hayward et al., 1991). These observa-
tions suggested that exogenous boosting of VZV T cells
using VZV vaccination might reduce the risk of herpes
zoster in populations at risk.
Vaccines
The VZV Oka vaccine strain was made by passage of a
clinical isolate, parent Oka virus, in human and guinea pig
embryo fibroblasts; its attenuation was demonstrated clinically
by administration to susceptible children (Gershon, 2001).
Investigations in the SCIDhu mouse model of VZV pathogen-
esis indicate that vaccine Oka attenuation is related to reduced
growth in skin whereas infectivity for T cells and dorsal root
ganglia is not different from parent Oka (Arvin, 2001a, 2001b;
Ku et al., 2005; Zerboni et al., 2005). The Oka/Merck pediatric
vaccine has a minimum potency of ¨1300 pfu and is
immunogenic and safe in healthy children. Recently, two
new formulations of this vaccine have been evaluated for the
prevention of herpes zoster. Immunization with a heat-
inactivated Oka/Merck vaccine preparation was associated
with a reduced incidence of herpes zoster to 13% during the
first year after autologous hematopoeitic cell transplantation
when given as one dose before and three doses after
transplantation (Hata et al., 2002). These severely immuno-
compromised vaccine recipients had early reconstitution of
VZV-specific CD4 T cell responses, which provided direct
evidence for the concept that cell-mediated immunity helps tomaintain VZV latency or prevents the progression of sub-
clinical reactivations to symptomatic herpes zoster. Higher
potency live attenuated Oka vaccines were developed and
evaluated for their potential to increase VZV cellular immunity
in healthy older adults. VZV-specific proliferation and res-
ponder CD4 T cell frequencies of 55- to 87-year-old subjects
were boosted to ranges observed in unimmunized younger
adults, ages 35–40 years, and higher responses persisted for
more than 2 years (Levin et al., 2003).
Oxman et al. have recently evaluated these high potency
Oka vaccine preparations, ranging from 18,700 to 60,000 pfu
(median 24,600 pfu) for their effects on herpes zoster in a large
placebo-controlled trial involving 38,546 healthy adults >60
years old; the median age in vaccines and placebo recipients
was 69 years, with 6.6% of vaccines and 6.9% of placebo
subjects being 80 years old (Oxman et al., 2005). The high
potency vaccines had >14-fold higher infectious virus content
than Oka/Merck pediatric vaccines. Active surveillance for
herpes zoster and laboratory confirmation was done for an
average of 3 years, in conjunction with assessments of zoster
severity, post-herpetic neuralgia, and health quality of life. The
herpes-zoster burden-of-illness score, which was the primary
endpoint, was reduced significantly in the vaccine cohort
compared to placebo recipients (P < 0.001), regardless of sex
or age <70 vs. >70 years. Post-herpetic neuralgia rates were
0.46 vs. 1.38 cases per 1000 person-years in vaccines and
placebo recipients (P < 0.001) and did not differ by sex or age.
The incidence of herpes zoster per 1000 person-years, which
was a secondary endpoint, was 5.42 in vaccines and 11.12 per
1000 person-years in the placebo cohort (P < 0.001), resulting
in a 51.3% efficacy for zoster prevention. Vaccine efficacy for
zoster prevention was 37.6% in subjects >70 years and 63.9%
among those <70 years old (P < 0.001). However, although the
incidence of zoster was higher, the effect of vaccination on
zoster severity was greater among those >70 years; therefore,
the impact on burden of illness remained 55.4% in >70 years
old adults. Overall, vaccination reduced the burden-of-illness
by 61.1% and incidence of post-herpetic neuralgia by 66.5% in
men and women >60 years old. The rates of serious adverse
events were low and did not differ between vaccine and
placebo recipients. Based on PCR analysis, all episodes of
herpes zoster were wild type VZV, indicating that the high
potency VZV vaccines did not cause herpes zoster. Although
immunologic studies have not been reported, the efficacy data
suggests that vaccination restored VZV T cells above a
threshold for protection from herpes zoster, reversing the
expected age-related decline in vaccine recipients.
Expectations for the future
VZV vaccines have now been successful for prevention
of varicella and reduction of the burden-of-illness caused by
herpes zoster. Questions that remain to be addressed include:
(1) Can new information about the molecular mechanisms of
VZV pathogenesis be used to design Fsecond generation_
live attenuated vaccines that have reduced potential to
A.M. Arvin, H.B. Greenberg / Virology 344 (2006) 240–249248infect T cells and neurons and are safe for use in high-risk
subjects?
(2) To what extent will inactivated VZV vaccines protect
patients with malignancy or solid organ transplants
against zoster?
(3) What is the duration of protection of live VZV vaccines
in healthy adults and what is the need, if any, for repeated
doses?
(4) Is the impact of live VZV vaccine on zoster burden of
illness maintained in the very old?
From a more general perspective, efficacy of the inacti-
vated VZV vaccine in hematopoeitic cell transplant reci-
pients and the high potency live attenuated zoster vaccine in
healthy older adults demonstrates that vaccination can
enhance naturally acquired immunity against a persistent
viral pathogen and that therapeutic vaccines may be useful
for reducing the disease burden from other herpes viruses in
healthy and high risk patients.
Summary
As the 21st century gets underway and Virology celebrates
its 50th anniversary, it appears likely that new and potent tools
to control four important viral diseases are on the horizon. It
will be exciting to see how the use of these tools improves the
human condition in the coming years.Acknowledgments
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